FOL-005
FOL-005 is in Phase 2 for androgenetic alopecia, developed by Follicum.
This programme is no longer being actively pursued.
- Developed by
- Follicum
- Current phase
- Phase 2
- Mechanism
- Signalling peptide
- Indications
- Androgenetic alopecia
- Also known as
- FOL005
- Last public activity
- March 2021
- Record confidence
- Low
Tests whether it works, at what dose, in a few hundred people.
Short protein fragments that mimic the body's own growth signals.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Development history
- Phase 1/2Phase 2
First Phase 2 trial on record: NCT03467412 — To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin
ClinicalTrials.gov ↗ - Phase 1/2
First Phase 1/2 trial on record: NCT02793557 — Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers
Follicum AB · n=209 · June 2020
To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin
Follicum AB · n=60 · February 2018
Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth
Follicum AB · n=44 · January 2016
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth — ClinicalTrials.gov
Cite this page
Hair Pipeline, "FOL-005 — development record", hairpipeline.com/pipeline/fol-005